Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870482 | 0.85 | MMP13 (0.33) | MMP13AAK1 | |
| SCHEMBL21134739 | 0.85 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL13707766 | 0.85 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL15845207 | 0.85 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL15845208 | 0.85 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL21153269 | 0.85 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL953166 | 0.82 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL1162878 | 0.82 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL1273585 | 0.82 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL7253134 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292340-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292340-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | LITAF, RIPK1, RIPK2 | MMP13 1046/4885AAK1 957/4885CYP1A2 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.